CI

At a glance

ClinicalIndex Comparison Record
Phase 1Recruiting· 20 target
Drug / intervention
Cervical cancer-specific CAR-T cellsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03356795
NCT03356795Phase 1RecruitingOn Track
CompareCT.gov

Multicenter Trial of Chimeric Antigen Receptor-Modified T Cells (CAR-T Cells) in the Treatment of Cervical Cancer

Shenzhen Geno-Immune Medical Institute·interventional·Posted Nov 29, 2017·Updated Jun 23, 2026

In Brief

A Phase 1 clinical trial evaluating Cervical cancer-specific CAR-T cells for Cervical Cancer. Currently recruiting, targeting 20 participants across 1 site.

Detailed Summary

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cells immunotherapy in patients who have GD2, PSMA, Muc1, Mesothelin or other markers positive cervical cancer. Another goal of the study is to learn more about the persistence and function of CAR T cells in the body.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Cancer
CountriesChina
Collaborators--

Timeline

Phase 1Recruiting
20182019202020212022202320242025202620272028202920302031
First PostedNov 29, 2017
Enrollment StartJun 1, 2026
Primary CompletionDec 31, 2029
Study CompletionDec 31, 2030
TodayJul 1, 2026
Enrollment to primary: 3.6 yearsPosted 8.6 years agoPrimary completion in 3.5 years

Arms & Interventions

Cervical cancer-specific CAR-T cellsexperimental

Peripheral blood mononuclear cells (PBMCs) of patients who have GD2, PSMA, Muc1 or Mesothelin positive cervical cancer will be obtained through apheresis, and T cells will be activated and modified to cervical cancer-specific CAR-T cells.

Biological: Cervical cancer-specific CAR-T cells

Interventions

Cervical cancer-specific CAR-T cellsbiological

1 infusion, for 1x10\^6\~1x10\^7 cells/kg via IV